The Lancet has published the positive full results ofUCB and Biogen’s Phase III PHOENYCS GO study of dapirolizumab pegol (DZP ...

The U.S. House Appropriations Committee has voted to increase Fiscal Year 2027 funding for lupus programs at the Department ...

New data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress of the investigational ...

In a new study, researchers found achieving low disease activity or remission is possible and meaningful for people with ...

This June, we recognize Men’s Health Month 2026 by honoring the strength, challenges and lived experiences of men with lupus.

Pharmaceutical company Johnson & Johnson announced new late-breaking results from its Phase 2 JASMINE study showing that investigational therapy nipocalimab significantly reduced disease activity in ...

The Department of Defense (DoD) has announced the availability of nearly $10 million in funding opportunities for high-impact lupus research through the Congressionally Directed Medical Research ...

The National Institutes of Health (NIH) is the largest funder of lupus research in the United States. The NIH's involvement in lupus research has spurred some of the most important medical ...

In a study published in the Annals of the Rheumatic Diseases researchers found that compounds detected in exhaled breath may offer a promising, noninvasive way to better understand and monitor ...